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Abstract: Down syndrome (DS) subjects are more likely to develop the clinical features of 
Alzheimer’s disease (AD) very early in the disease process due to the additional impact of 
neuroinflammation and because of activation of innate immunity. Many factors involved in the 
neuropathology of AD in DS, including epigenetic factors, innate immunity and impaired 
haematopoiesis, contribute significantly towards the pathophysiology and the enhanced ageing 
processes seen in DS and as a consequence of the triplication of genes RUNX1, S100β and OLIG2, 
together with the influence of proteins that collectively protect from cellular defects and 
inflammation, which include hepcidin, ferritin, IL-6 and TREM2. This study is aimed at determining 
whether genetic variants and inflammatory proteins are involved in haematopoiesis and cellular 
processes in DS compared with age-matched control participants, particularly with respect to 
neuroinflammation and accelerated ageing. Serum protein levels from DS, AD and control 
participants were measured by enzyme-linked immunosorbent assay (ELISA). Blood smears and 
post-mortem brain samples from AD and DS subjects were analysed by immunohistochemistry. 
RUNX1 mRNA expression was analysed by RT-PCR and in situ hybridisation in mouse tissues. Our 
results suggest that hepcidin, S100β and TREM2 play a critical role in survival and proliferation of 
glial cells through a common shared pathway. Blood smear analysis showed the presence of RUNX1 
in megakaryocytes and platelets, implying participation in myeloid cell development. In contrast, 
hepcidin was expressed in erythrocytes and in platelets, suggesting a means of possible entry into 
the brain parenchyma via the choroid plexus (CP). The gene product of RUNX1 and hepcidin both 
play a critical role in haematopoiesis in DS. We propose that soluble TREM2, S100β and hepcidin 
can migrate from the periphery via the CP, modulate the blood–brain immune axis in DS and could 
form an important and hitherto neglected avenue for possible therapeutic interventions to reduce 
plaque formation. 
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Down syndrome (DS) is the leading genetic cause of intellectual disabilities in live-
born infants and is caused by the presence of an extra copy of chromosome 21 (Hsa21) [1–
3]. People with DS have characteristic phenotypes including growth retardation, cognitive 
impairments, premature ageing, abnormal haematopoiesis, various forms of leukaemia 
and immune disorders [1–3]. There are many factors likely to be involved in the 
development and progression of the neuropathology of Alzheimer’s disease (AD) and in 
the enhanced ageing processes in DS, including epigenetic factors, innate immunity and 
impaired haematopoiesis [3–6]. The mechanism of the early onset of AD pathology in DS 
is not fully understood, but the over-expression of certain genes on Hsa21, particularly in 
the Down syndrome critical region 1 (DSCR1) that also includes the amyloid precursor 
protein (APP), Cu/Zn superoxide dismutase (SOD1), RUNX1 (a transcription factor) [7] and 
S100β, play crucial roles [8,9]. Studies have demonstrated that dosage-dependent 
increases in Hsa21 gene expression do occur in trisomy 21 (T21) [10,11]. The many 
triplicated genes on Hsa21, particularly SOD1 and S100β, have been associated with 
oxidative stress, and their over-expression may contribute to a genetic imbalance in DS, 
and potentiate the development of reactive oxygen species (ROS) [12–14]. However, it is 
unclear whether the entire transcriptome is disrupted, or whether there is a more 
differential change in the expression of chromosome 21 genes [15,16]. It has been 
hypothesised that gene expression changes in Hsa21 are likely to affect the expression of 
genes located on other chromosomes through the modulation of transcription factors, 
immune regulation and other factors [17,18]. It is proposed that, in addition to primary 
gene dosage effects, secondary (downstream) effects on disomic genes are likely to have 
a major role in the development of the wider phenotype in the people with aneuploidies 
in general and DS in particular [9,10]. 
Triosomy-21 is associated with enhanced megakaryocytic and erythroid precursor 
expansion, and gene-encoded transcription factors RUNX1, ERG, OLIG1 and OLIG2 
influence haematopoietic fates in DS [19–22]. Mutations in the GATA-1 and RUNX1, 
which encode transcription factors, are central to the normal development of the erythroid 
and megakaryocytic lineages and are found in cases of myeloid leukaemia in DS children, 
but the incidence decreases in adulthood [23,24]. 
A key concern in adult DS subjects is an increase in vulnerability to the development 
of AD, which typically has an age of onset between 40 and 60 years [16,25]. A link between 
DS and AD in terms of dementia and neuropathological features has been established [26–
29]. All adults with DS over the age of 40 years display neuropathological hallmarks of 
AD, including senile plaques (SPs) and neurofibrillary tangles (NFTs) [29–32]. SPs are 
primarily composed of amyloid beta peptide (Aβ42), a highly fibrillogenic form of the 
peptide, produced via sequential cleavage of the amyloid precursor protein (APP) by beta- 
and gamma-secretases [33]. The triplication of chromosome 21 in DS leads to the increased 
production of APP in a dose-dependent manner and could increase the deposition of Aβ42 
protein, leading to the development of NFTs, one of the pathophysiological features of 
AD [34]. Additionally, high Aβ42 accumulation is toxic which could enhance the 
formation of ROS and oxidative stress in neurons, leading to neuroinflammation and 
premature cell death [13,35,36]. 
Aβ plaque deposition is an early event in DS brain, and Aβ and iron storage protein 
ferritin have been shown to co-localise in the vascular amyloid deposits of plaque in post-
mortem AD brains [14,37–39]. Iron is involved in many fundamental biological processes 
in the brain, including oxygen transportation, DNA synthesis, mitochondrial respiration, 
myelin synthesis and for key enzymes involved in biosynthesis of, for example, 
neurotransmitters [40,41]. Many proteins are involved in iron homeostasis, including 
ferritin, hepcidin, transferrin and transferrin receptors, ferroportin (FPN) and divalent 
metal protein 1 (DMT1) [38,42–44]. Ferritin is an iron storage protein, and is often 
accompanied by abnormal iron homeostasis in inflammation that leads to systemic 
hypoferritinaemia [45]. Hepcidin is a member of the defensin family of antimicrobial 
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cationic peptides that plays a significant role in host defence and innate immunity on 
account of its broad antibacterial and antifungal properties [46,47]. Hepcidin synthesis by 
hepatocytes is stimulated when body iron levels increase during systemic inflammation 
and is usually suppressed by hypoxia and increased erythroid activity [48,49]. Hepcidin 
is distributed in the circulation and extracellular fluid of cells that express the hepcidin 
receptor, ferroportin (FPN) [50]. This ferrous iron permease is the only known iron 
exporter expressed by mammalian cells, and hepcidin inhibits iron efflux by binding to 
the FPN on the cell surface and triggering the internalisation and lysosomal degradation 
of the complex [51]. 
Iron trafficking in the brain is less well-understood than systemic iron metabolism, 
although proteins implicated in iron transport and storage are common to both systems 
[52]. Hepcidin and its receptor ferroportin’s immunoreactivity are evident in neurons and 
glial cells, where it was suggested that both the proteins could play a role in iron 
homeostasis in the central nervous system [53]. It was reported that APP may bind to 
ferroportin to facilitate neuronal iron export, and that disturbance in this process may be 
implicated in AD neuropathology [54]. 
Inflammation has long been suspected to be a major player in the aetiology of AD 
dementia (ADD) in DS, and dysfunction of APP processing is believed to be the key 
upstream factor in neuroinflammation and for activation of innate immunity, with both 
being considered early events in the genesis of ADD [55]. In DS and in late-onset AD 
(LOAD), neuroinflammation has been linked to both the exacerbation of SP and NFT 
pathology, as well as the clearance of Aβ from amyloid plaques [56–58]. The main cell 
types involved in the brain neuroinflammatory responses are microglia, astrocytes and to 
a lesser extent, the peripheral and meningeal macrophages [39,55,59]. Microglia when 
activated release a cocktail of inflammatory cytokines and chemokines [60,61]. These are 
often triggered in a subcellular compartment known as the inflammosome, where IL-6 
and IL-1β are the main pathological mediators causing cytokine release [39,61]. 
Besides iron levels in the circulation, inflammation is yet another factor regulating 
hepcidin transcription in the hepatocytes. Inflammatory cytokines, mainly in the form of IL-6, 
are released during inflammation and induce hepcidin expression in the hepatocytes via the 
JAK/STAT3 signalling pathway, leading to phosphorylation of STAT3, its translocation to the 
nucleus and activation of the hepcidin gene [62]. The identification of a novel variant in the 
gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2) has also 
refocused attention on inflammation as a major contributing factor in AD. Variants in TREM2 
(rs75932628, substitution of T to C, changes in R47H mutation) significantly increase the risk 
of developing late-onset AD, by three-fold [29,63–66]. TREM2 is a pattern recognition receptor, 
expressed on macrophages and microglia. It has the function to detect lipid and Aβ that 
stimulate phagocytosis and induce an innate immune response [65,67]. 
The aim of our study was to explore the possible role of the proteins triplicated in 
T21 and how these proteins are involved in transport of amyloid protein, iron metabolism 
and influence neuroinflammation and cellular damages seen in DS. We evaluated 
hepcidin, ferritin, SOD1, S100β, IL-6 and TREM2 expression in serum and post-mortem 
brain samples to determine the crosstalk between inflammation and iron dysregulation in 
normal ageing and in DS pathology and to ascertain how these changes in 
neuroinflammation could play a role in the acceleration of ageing in DS. To explore 
progression of abnormalities in iron homeostasis in DS, we also investigated blood smears 
from DS and age-matched controls to determine the role of RUNX1 and hepcidin in the 
development of the erythroid and megakaryocytic lineages. 
2. Materials and Methods 
2.1. Ethics and Participants 
The National Research Ethics Committee of the East of England granted approval for 
the study. The Cambridge Health Authorities Joint Ethics Committee granted ethical 
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approval for the use of human brain tissue and serum samples (Project ref no: 
REC:15/WM/0379). Written consent was obtained from controls and from adult DS 
participants who had the capacity to consent. Verbal assent was obtained from 
participants with DS, who lacked the capacity for consent and written assent, and was 
provided by an appointed consultee, in accordance with the English and Welsh Mental 
Capacity Act of the UK (2005). Information on older controls (n = 25), younger controls (n 
= 25) and DS participants (n = 47) has been reported in previous publications [29,66]. 
2.2. Assessment of Dementia Status 
Dementia status assessment was undertaken as described previously using the 
CAMDEX-DS informant interview and the CAMCOG-DS neuropsychological assessment 
[68]. 
2.3. Blood and Serum Collection 
Whole blood and serum samples were collected from human controls (n = 50, aged 
between 30 and 85 years), with intact cognitive functioning and devoid of neurological 
and mental illness, and from 47 participants with DS (aged between 32 and 70 years) and 
assessed at our Research Centre. All blood samples were collected for serum in BD 
vacutainer SST advance tubes (containing inert gel barrier and clot activator coating). 
Serum and plasma were separated immediately by centrifugation at 2465× g for 6 min at 
4 °C, aliquoted, and stored at −80 °C until analysis. Biochemical and haematological 
profiles including serum iron were analysed by pathology laboratories at Addenbrooke’s 
Hospital, Cambridge University NHS Foundation Trust, Cambridge, UK. 
2.4. Human Post-Mortem Brain Sections 
Human post-mortem brain tissues from controls (mean age 60 ± 15 years) and from 
people with DS (mean age 60 ± 15 years) (N = 10 in each group) were provided by the 
Cambridge Brain Bank (Table 1). The Cambridge Health Authorities Joint Ethics 
Committee granted ethical approval for use of human brain tissues and serum samples 
(Project ref no: REC:15/WM/0379). All methods have been described in our previous 
publications [29,39,65,66]. 
Table 1. Characteristics of post-mortem (PM) brain samples of DS and age-matched control study population, showing 
age, gender, post-mortem time delay, Braak stages and cause of death. 
Case Number Category Age Gender PM Delay (h) Braak Stage Cause of Death 
Down Syndrome (DS)       
DS1 DS 56 F 6 6 Not known 
DS2 DS 76 F 18 6 Septicaemia 
DS3 DS 46 F 8 2 Not known 
DS4 DS 52 M 24 6 bronchopneumonia 
DS5 DS 64 M 31 6 Not known 
DS6 DS 66 F 26 5 Not known 
DS7 DS 67 M 8 5/6 
Alzheimer’s disease (AD), 
Cerebrovascular disease (CVD) 
DS8 DS 52 F - 6 AD, Lewy body dementia 
DS9 DS 52 M - 5 Traumatic brain injury (TBI) 
DS10 DS 76 F 18 6 Dementia 
Controls       
C1 Normal 66 M 10.3 5 Cerebrovascular Disease/Dementia 
C2 Normal 45 F 43.3 0 
End stage renal failure/diabetic 
nephropathy 
C3 Normal 54 F 10.3 0 
Metastatic Myxoid 
Liposacroma/Bronchopneumonia 
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C4 Normal 52 F 30.3 1 Bronchogenic Cancer 
C5 Normal 75 F 24 2 Cancer of the Ovary 
C6 Normal 66 F 29.3 2 Metastatic Breast Cancer 
C7 Normal 83 M 45 0 Not known 
C8 Normal 68 M 48 0 Not known 
C9 Normal 60 F 60 0 Not known 
C10 Normal 66 M 74 0 Not known 
2.5. Blood Slide Preparation 
A drop of blood placed on a slide was spread as described previously [29,61]. The 
slide was air-dried and fixed in 100% methanol and stored at 4 °C. Further investigations, 
including immunohistochemistry, were performed on stored fixed slides, as described 
later. Bone marrow slides from DS participants were fixed with 100% methanol and stored 
at 4 °C. 
2.5.1. Animals 
Three-month-old C57/Bl6 mice were purchased from Charles River and bred for the 
experiments at the University of Cambridge Bioscience facility (UBSS, at John van Geest 
Centre for Brain repair animal facility). All experiments were performed according to the 
“Animal (Scientific Procedures) Act 1986” and the “Guidance of the Operation of ASPA 
2014” and were approved by the Ethical Committee of the UK Home Office. 
2.5.2. Mouse Tissue Preparation 
All animals were housed under standard conditions (12 h light–dark cycle, 20 °C 
ambient temperature) with free access to food and water. Animals undergoing perfusion 
were anaesthetised with rising concentrations of CO2 followed by terminal injection of 
Euthatal (0.3 mL per 100 g of body weight). Collection of fresh tissues was performed after 
raising the concentration of CO2 followed by cervical dislocation. For histochemical 
analyses, animals were anaesthetised with pentobarbitone and flash-perfused 
transcardially with 0.9% saline, followed by 4% (v/v) paraformaldehyde (PFA) in 0.1 M 
phosphate buffer saline (PBS, pH 7.4). Brains were removed, post-fixed for 4 h in the same 
fixative, and then cryoprotected with 30% sucrose in 0.1 M PBS. Brains and other tissues 
(spleen and duodenum) were sectioned by microtome as described previously [38]. For in 
situ hybridisation, unfixed tissues were carefully dissected from C57/Bl6 mice from 
various brain regions and different organs, including spleen, lung, duodenum and 
embryos (embryonic day 16, ED16), and snap-frozen in dry ice until they were analysed 
by in situ hybridisation. 
2.5.3. RNA Isolation and RT-PCR 
Total RNA was extracted from ED16 brain, ED16 whole body and adult mouse 
tissues. Approximately 50 mg of tissue was placed in 1 mL of TRIzol reagent (Invitrogen) 
following the manufacturer’s instructions and then purified using a RNeasy Mini kit 
(Qiagen). RNA was treated with DNase I and cDNA synthesised from 2 g of the treated 
RNA using a SuperScript III reverse transcriptase kit (Invitrogen) with random hexamer 
primers. Real-time PCR was performed using iQ Supermix SYBR Green 2 by Bio-Rad on 
the Bio-Rad iCycler (www.bio-rad.com (accessed on 15 January 2021)) according to the 
manufacturer’s protocols. PCR reactions were performed in triplicate. The primers used 
for amplification were RUNX1 (Forward Primer: 
5′CAGGCAAGATGAGCGAGGCGTTG3′ and Reverse primer: 
5′CAACCTGGTTCTTCATGGCTGC3′, product size 320 bp), using a program of 95 °C for 
3 min, 30 cycles of 95 °C for 30 s, 60 °C for 30 s and 72 °C for 1 min. The GAPDH 
housekeeping gene was chosen as the reference gene. GAPDH (Forward Primer: 
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5′CGGAGTCAACGGATTTGGTCGTAT3′, Reverse primer: 
AGCCTTCTCCATGGTGGTGAAGAC, (product size 500 bp). 
2.5.4. In Situ Hybridisation (ISH) 
Brain tissues and other organs were prepared for in situ hybridisation and probed as 
described previously [61]. To synthesise DIG-labelled RNA probes, the target RUNX1 
cDNA was amplified by PCR using primers designed on the basis of the mouse RUNX1 
cDNA sequence used in RT-PCR. The primers used for DIG labelling were: RUNX1-insF: 
5′TAATACGACTCACTATAG GCAGGCAAGATGAGCGAGGCGTTG3′, and RUNX1-
insR: 5′ATTTAGGTGACACTATAGAGCAACCTGGTTCTTCATGGCTGC3′, sequenced 
and homology checked by BLAST search (NCBI database). In vitro transcription reactions 
were performed using dig-UTP RNA labelling mix and SP6 or T7 RNA polymerase 
(Roche, Mannheim, Germany). The sense and anti-sense DIG-labelled probe was prepared 
to assess hybridisation stringency, and freshly frozen mouse tissues from liver, brain, 
duodenum and embryonic body (ED16). 
This method has been described in detail in our previous publications [53,61]. Briefly, 
ISH with DIG-labelled probe was carried out on liver, brain and other embryonic tissue 
sections fixed in 4% PFA and permeabilised in 0.1 M PBS with 0.5% Triton X-100, and 
acetylated by incubation in triethanolamine solution. Pre-hybridisation was performed 
for 3 h at 62 °C and then hybridised with DIG-labelled probes (100 ng/mL) in the same 
buffer overnight at 62 °C. Stringent washing was performed in 0.2× SSC for 1 h at 62 °C. 
For the detection of DIG-labelled hybrids, the slides were equilibrated in maleic acid 
buffer (MAB) at room temperature (RT) with 1% blocking reagent made in MAB (blocking 
buffer), and then for 1 h with alkaline phosphatase-conjugated anti-DIG antibodies 
(Roche, Mannheim, Germany) diluted 1:5000 in blocking buffer. The slides were washed 
and incubated overnight in colour development buffer (2.4 mg levamisole (Sigma), 45 μL 
4-nitroblue tetrazolium (Sigma) and 35 μL 5-bromo-4-chloro-3-indolyl-phosphate 
(Sigma)). The reaction was stopped in neutralizing buffer (0.01 M Trizma base and 0.001 
M EDTA, pH 8) and sections were mounted in PBS–glycerol and a coverslip was applied 
over the section on the slide. Non-specific binding was analysed using sense probes. 
2.5.5. SDS-PAGE Gel and Western Blotting 
Protein samples were prepared from human serum (DS and age-matched controls, n 
= 20). Twenty μg protein samples were separated on 4–12% Nu-PAGE Bis-tris (Bis (2-
hydroxyethyl)-amino-tris (hydroxymethyl)-methane) gradient gels and transferred to 0.2 
μm pore size PVDF for Aβ42, hepcidin and S100β, and 0.45 μm pore size PVDF 
membranes for SOD1, FTL, FPN, TREM2 and albumin using the NuPAGE electrophoresis 
system (Invitrogen). Membranes were incubated with different antibodies, i.e., anti-β 
amyloid (Covance, SIG 39320), SOD1 (Abcam, ab252426), S100β (Abcam, ab218514), anti-
ferritin light chain (FTL, Abcam, ab69090), anti-FPN (Abcam, ab85370), anti-hepcidin 25 
(Abcam, ab30760), anti-TREM2 (Abcam, ab86491) and anti-albumin (Abcam, ab10241) 
antibody, in blocking buffer for 24 h at 4 °C, and then washed three times with 0.1 M Tris 
saline buffer containing 1% Tween 20 (TBST), followed by incubation for 1 h at RT with 
HRP-conjugated secondary antibodies, anti-rabbit IgG (1:3000, DAKO) or anti-mouse IgG 
(1:3000; DAKO) antibodies. Binding was detected with ECL Plus chemiluminescence 
reagents. 
2.6. Solid Phase Enzyme-Linked Immunosorbent Assay (ELISA) 
The human serum ferritin level was measured with the human ferritin ELISA kit 
(Abcam, catalogue number ab108698) and serum hepcidin (human hepcidin Quantikine 
ELISA kit, catalogue number DHP250), IL-6 (human IL-6 Quantikine ELISA kit, R&D, 
catalogue number S6050) and TREM2 (ThermoFisher, catalogue number EH464RB) 
according to the manufacturer’s instructions. Briefly, for the detection of hepcidin, 96-well 
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culture plates were incubated overnight with monoclonal antibody (R&D, MAB83071) or 
anti-hepcidin capture antibody (1 μg/mL) (R&D system, catalogue number 842127). The 
following day, the plates were washed three times with washing buffer (0.05% Tween 20 
in 0.1 M phosphate buffer saline (PBS) pH 7.4) and blocked in blocking solution (1% BSA 
and 0.05% Tween 20 in 0.1 M PBS) for 2 h, at RT. After blocking, the plates were washed 
three times with washing buffer and loaded with 10 μL plasma into 90 μL blocking 
solution and incubated for 4 h, at RT. All experiments were performed in quadruplicate 
unless otherwise specified. A recombinant human protein (R&D, catalogue number 
842129) was diluted in assay buffer in a two-fold serial dilution and used for the standard 
curve, with a concentration range of 1000, 500, 250, 125, 62, 31, 15 and 0 pg/mL. After 4 h 
of incubation, the samples were removed, and the plates were washed three times for 5 
min with washing buffer before incubation for 2 h at RT for detection with a biotinylated 
rabbit polyclonal anti-human hepcidin (Abcam, ab30760) antibody (1 μg/mL), diluted in 
blocking buffer. After three further washing steps, the plates were incubated with anti-
rabbit HRP-conjugated secondary antibody (1:4000) for 1 h followed by three washes. 
Then, 100 μL of 1-Step ULTRA tetramethylbenzidine (TMB-ELISA, ThermoScientific) was 
added for ~30 min at RT. Finally, 100 μL of 2 M H2SO4 was added to quench the reaction. 
Colorimetric quantification was performed with an Infinite M200 plate reader (Tecan) at 
450/540 nm. 
2.7. Antibodies 
A polyclonal rabbit anti-hepcidin 25 (Abcam, ab30760), recognising a 2.8 kDa protein 
[53], monoclonal antibody (MAB) human anti-ferritin light chain (Abcam, ab69090), 
human anti-ferritin heavy chain (Abcam, ab65080), anti-DMT1 (Abcam, ab123085), anti-
FPN (Abcam, ab85370), anti-CD42b (Abcam, ab104704), anti-rabbit polyclonal 
glycophorin (Abcam, ab196568), anti-GFAP (Abcam, ab48050), anti-CD68 (Sigma-Aldrich, 
AMAB98073), MAB anti-CD11b (Thermo Fisher, mAbM1/70), GFAP (Abcam, ab48050), 
MAB anti-Iba1 (Thermo Fisher, MAB M1/70), polyclonal anti-Iba1 (Wako, catalogue 
number 019-19741), MAB anti-IL-6 (ThermoFisher, catalog number M620), MAB IL-1β 
(ThermoFisher, ILB1-H67), MAB anti-β amyloid 42 (Covance, SIG 39320), anti-phospho-
tau (AT8, ThermoFisher, MN1020), SOD1 (Abcam, ab252426), S100β (Abcam, ab218514), 
RUNX1 (Sigma-Aldrich, HPA004176) and OLIG2 (Santa Cruz Biotechnology, sc-365644) 
were used for IHC or Western blotting. The following secondary antibodies were used: 
biotinylated goat anti-rabbit-Ig and biotinylated horse anti-mouse (both from Vector 
Laboratories, 1:250 for IHC), Alexa Fluor 568-labelled donkey anti-mouse-Ig, Alexa Fluor 
488-labelled donkey anti-rabbit-Ig and Alexa Fluor 568-labelled donkey anti-goat-Ig (all 
from Invitrogen, 1:1000 for immunofluoresence). 
2.8. Immunohistochemistry (IHC) 
PFA fixed tissues were first quenched with 5% hydrogen peroxide and 20% methanol 
in 0.01 M PBS for 30 min at RT, followed by three rinses for 10 min in 0.01 M PBS. Non-
specific binding sites were blocked using blocking buffer (0.1 M PBS, 0.3% Triton-X100 
and 10% normal goat serum for polyclonal antibodies or 10% normal horse serum for 
monoclonal antibodies) for 1 h, at RT. Tissue sections were incubated overnight with the 
primary antibody diluted in blocking buffer. Binding of the primary antibody was 
detected using a biotinylated secondary antibody followed by an avidin-biotin complex 
conjugated to peroxidase (Elite standard kit SK6100, Vector Laboratories) and DAB 
substrate (ABC substrate SK-4200, Vector Laboratories). 
2.9. Immunofluorescence (IF) 
Brain and other sections were blocked using blocking buffer (0.1 M PBS, 0.3% Triton 
X100, 10% normal donkey serum) for 1 h, at RT, then incubated overnight at 4 °C with 
primary antibody diluted in blocking buffer. Alexa Fluor-conjugated secondary 
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antibodies were used for detection and samples were counterstained with 4′6-diamidino-
2-phenylindole (DAPI, Sigma). Sections were then mounted on glass slides with 
coverslips using Fluoro Save (Calbiochem). 
2.10. Microscopy 
Bright-field images were taken and quantified using Lucia imaging software and a 
Leica FW4000 upright microscope equipped with a SPOT digital camera. Fluorescence 
images were obtained using a Leica DM6000 wide-field fluorescence microscope 
equipped with a Leica FX350 camera with 20× and 40× objectives. Images were taken 
through several z-sections and de-convolved using Leica software. A Leica TCS SP2 
confocal laser-scanning microscope was used with 40× and 63× objectives to acquire high-
resolution images. 
2.11. Statistical Methods 
Data were analysed by paired Student’s t-test (two-tailed) for two group comparison, 
or by ANOVA for multiple comparison testing. Values in the figures are expressed as 
mean ± SEM. A one-way ANOVA was used for comparison of data among control, AD 
and DS, and was conducted with IBM-SPSS statistics 19 software. Significance was 
analysed using GraphPad, and p-values ≤ 0.001 were considered significant and are 
indicated in the corresponding figures and figure legends. 
3. Results 
3.1. Characterisation of Senile Plaques in DS Brain 
Senile plaque (SP) formation is the key neuropathological hallmark in AD and DS, 
and SPs are primarily composed of amyloid beta peptide (Aβ42). To characterise the SP 
formation, the brain sections from superior frontal gyrus (SFG), mid temporal gyrus 
(MTG) and hippocampus from DS and control brains (n = 10 in each group, average age 
between 42 and 70 years) were analysed by IF and imaged with confocal microscopy, 
using antibodies specific to Aβ42 (6E10), phospho-tau (pTau, with AT8 antibody), 
hepcidin and TREM2. In a younger (42 years old) DS brain, we stained SFG sections with 
Aβ42 antibody and found abundant cotton wool appearance of SPs throughout the cortex 
(Figure 1A, white arrows highlight the selected area of plaque formation). Most of the 
plaques were formed from a cluster of small swollen neurites surrounded by neuropil 
without an amyloid core, whereas in the periphery, some other mature SPs were 
surrounded by a halo of Aβ42 (Figure 1A, short arrow highlights the selected areas of 
plaque formation). To compare with non-DS AD brain, a section was stained with Aβ42 
and pTau and analysed by confocal microscope. We observed a mature SP that contained 
many pTau-positive dystrophic neurites in the centre, with distinct Aβ42-positive 
astrocytes in the surrounding area (Figure 1B). For further analysis, another DS brain 
section from MTG was stained with pTau and TREM2, a well-known inflammatory 
marker. NFTs were visible in the core of the plaques with some co-localisation with 
TREM2 in the SP and close by (Figure 1C). A confocal image of DS MTG showed pTau-
positive NFT visible very close to a blood vessel (Figure 1D). As most of the SP is 
composed of astrocytes, another DS SFG sample was stained with an astrocytic marker 
(GFAP) and imaged using confocal microscopy. The SP was composed of GFAP-positive 
astrocytes and it was surrounding the endothelial layer of blood vessels (Figure 1E). To 
compare with controls, one SFG from a control brain section was stained with Aβ40 and 
hepcidin. Amyloid proteins were found to be evenly distributed in the neuronal cell body, 
axons and dendrites, whereas hepcidin was present in the cell bodies only (Figure 1F). 
These findings indicate that not only neurons but also astrocytes contribute a great deal 
to plaque formation. 




Figure 1. Characterisation of senile plaques (SP) in DS brain. To characterise the SP formation, the DS, AD and control 
brain sections from the superior frontal gyrus (SFG) and mid temporal gyrus (MTG) were labelled with double 
immunofluorescence using anti-Aβ42, phospho-tau (with AT8 antibody), anti-hepcidin and anti-TREM2, then 
counterstained with DAPI for nuclei (blue) and imaged with confocal microscopy. In DS brain, sections were stained with 
Aβ42 antibody, and an abundant cotton wool appearance of senile plaques (SP) was seen throughout the cortex (A), white 
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arrows highlight the selected area of plaque formation). One AD brain section when stained with Aβ42 and pTau and 
analysed by confocal microscope showed a mature SP that contained many pTau-positive dystrophic neurites in the 
centre, with distinct Aβ42-positive astrocytes in the surrounding area (B). Another DS brain section from MTG was stained 
with pTau and TREM2, and neurofibrillary tangle (NFT) was visible in the core of the plaques, with some co-localisation 
with TREM2 in the SP and close by (C). In a confocal image of DS, MTG showed pTau-positive NFT visible very close to 
blood vessels (D). SFG samples from DS brain when stained with GFAP showed astrocytes surrounding the endothelial 
layer of blood vessels (E, short arrow highlights the blood vessel wall). One SFG from a normal brain section was stained 
with Aβ40 and hepcidin, and amyloid proteins were found to be evenly distributed in the neuronal cell body, axons and 
dendrites, whereas hepcidin was present in the cell bodies (F). Scale bar: (A,C) = 50 μm, (B–F) = 25 μm. 
3.2. Hepcidin and S100β-Positive Activated Damaged Astrocytes Seen around the Wall of Blood 
Vessels in DS 
Hepcidin is a key iron regulatory protein and is involved in iron transport from the 
brain parenchyma via astrocytes. To evaluate the expression of hepcidin in the astrocytes, 
sections from the cortex close to the blood vessels were analysed. In DS brain, GFAP-
positive activated astrocytes were present around the SP and surrounding the blood 
vessels that also co-localised with hepcidin in the endothelial cells (Figure 2A–C, indicated 
with an arrow). In the DS brain, particularly in the SP, a dense core of GFAP-positive 
astrocytes were visible in a very organised form, where hepcidins located in the vesicles 
and co-localised in the astrocytes (Figure 2D–F). In a control brain section, normal 
astrocytes with fine processes were visible and co-localised with hepcidin in the cell 
bodies (Figure 2G). A large number of small vesicles (exosomes) carrying hepcidin were 
present in the SP of the DS cortex and its surroundings (Figure 2H). Hepcidin expression 
was visible in the periphery of blood vessels (in the endothelial cells) and co-localised with 
the GFAP-positive astrocytes in the DS brain (Figure 2I). Very strong co-localisation of 
hepcidin was noticed in layers I and II of the cortices (Figure 2I). 
S100β promotes development and maturation in the mammalian brain, and its role 
in the cascade of glial changes associated with neuroinflammation is well-known [69]. 
Therefore, we stained brain sections from SFG of control and DS subjects with S100β and 
inflammatory protein TREM2 and analysed them by confocal microscopy. In control 
brain, normal astrocytes with thin filaments of processes of end-feet were present and 
surrounded the blood vessels, and were positive for S100β (Figure 2J). TREM2 were 
present in the astrocyte’s end feet carrying soluble TREM2 and co-localising in the cell 
bodies (Figure 2J–L). Some of the astrocyte’s filaments were directly connected to the 
endothelial lining of blood vessels (Figure 2J–L). However, in DS brain, S100β-positive 
activated astrocytes were disorganised and aggregated around the blood vessel walls, 
indicating severe endothelial cell damage of blood vessels (Figure 2M–O). This finding 
suggests that S100β is important in astrocytes and cellular changes seen in ageing-
associated DS pathology, particularly of gliosis. 




Figure 2. Hepcidin and S100β-positive activated damaged astrocytes seen around the wall of blood vessels in DS. DS 
and control brain sections from the cortex and close to the blood vessels labelled with double immunofluorescence (IF) 
using anti-hepcidin (green), anti-GFAP (red), counterstained with DAPI for nuclei (blue) and imaged with confocal 
microscopy. In DS brain sections, GFAP-positive activated astrocytes were present around the SP and surrounding the 
blood vessels (A–C, indicated with an arrow). Hepcidin expression was visible in the endothelial cells of blood vessels (B) 
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and co-localised with the GFAP-positive astrocytes in the DS (E,F). In the senile plaques, GFAP-positive astrocytes were 
well-organised around the plaque formation (D–F). In the control brain section, normal astrocytes with fine processes 
were visible and co-localised with hepcidin in the cell bodies (G). A large number of small vesicles carrying hepcidin were 
present in the SP of the DS cortex and its surroundings (H). Very strong co-localisation of hepcidin with GFAP was noticed 
in layers I and II of the cortex (I). DS and control brain sections from SFG were stained with S100β and inflammatory 
protein TREM2. In control brain sections, thin filamentous processes of end-feet of normal astrocytes were present 
surrounding the blood vessels, positive for S100β and directly connected to the endothelial lining of blood vessels (J). 
TREM2 was present in the end-feet of astrocytes carrying soluble TREM2 (K) and co-localised in the cell bodies (J–L). In a 
DS brain section, S100β-positive activated astrocytes were found disorganised and aggregated around the blood vessel 
walls, indicating severe damage of endothelial cells of blood vessels (M–O). Scale bar: (A–C) = 25 μm, (D–F) = 15 μm, (G–
O) = 30 μm. 
3.3. Hepcidin and Ferroportin Expression in the Oligodendrocytes of White Matter Tract 
Hepcidin and ferroportin (FPN) could be involved in glial activities not only in 
astrocytes but also in oligodendrocytes to transport amyloid and other proteins through 
the white matter tract (WMT). To assess this aspect, we extended our investigation of 
hepcidin and FPN in white matter (WM) of controls and DS brains. Brain sections from 
SFG, MTG and hippocampus (HP) from DS and controls were then analysed by IHC using 
antibodies specific to Aβ42 (6E10), hepcidin and FPN, and using DAB stain. In the SFG of 
DS brain, abundant Aβ42-positive SPs were observed in the neocortex (Figure 3A, black 
arrows highlight the selected area of plaques formed) and hepcidin was also visible in the 
SPs (Figure 3B). In control brains (cortex), abundant hepcidin was seen in the neurons and 
in the neuropils (Figure 3C), whereas in the DS cortex, hepcidin staining was faint, present 
only in the neurons and glial cells (Figure 3D). In DS brain, hepcidin was present in the 
granule cells of the dentate gyrus (DG) (Figure 3E), and in the basal ganglia (BG) as 
punctate accumulation of vesicular hepcidin in the cell bodies and around the blood 
vessels (Figure 3F). In the WMT, typical hepcidin staining was visible as normally 
appearing in the control brain (Figure 3G), whereas a very granular appearance was 
visible in the cell bodies of oligodendrocytes in the DS brain (Figure 3H). FPN expresses 
in the pyramidal neurons of HP in control brain (Figure 3I), however very faint staining 
was seen in the pyramidal neurons in the DS brain (Figure 3J). Similarly, in DS brain, FPN 
expression was very faint and irregular in the WMT (Figure 3K). 




Figure 3. Hepcidin and ferroportin expression in the oligodendrocytes of white matter tract. DS brain sections from SFG 
stained with DAB, anti-Aβ42 and hepcidin antibody revealed strong signal of SPs, positive for Aβ42 and visible 
throughout the cortex (A, black arrows highlighting the selected area of plaque formation), hepcidin was visible in SPs 
(B). In control brains (cortex), abundant hepcidin was seen in the neurons and in the neuropils (C); in contrast, in the DS 
cortex, hepcidin staining was faint, present only in neurons and glial cells (D). In DS brain, hepcidin was present in the 
dentate gyrus (DG) granule cells (E), and in the basal ganglia (BG) as punctate accumulation of vesicular hepcidin in the 
cell bodies and around the blood vessels (F). Normal hepcidin staining was visible in the WMT, in the control brain (G), 
whereas very granular appearance was visible in the cell bodies of oligodendrocytes in the DS brain (H). Normal FPN 
expresses in the pyramidal neurons of HP in control brain (I), however, very faint staining was seen in the DS brain (J). 
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Similarly, in DS brain, FPN expression was very faint and irregular in the WMT (K). Scale bar: (A,E,G–H) = 50 μm, (B–D) 
= 25 μm, (F,I–K) = 30 μm. 
3.4. DMT1, FPN and Hepcidin Regulate Endothelial Transport and SOD1, Modulating Redox 
Balance in the DS Brain 
The function of iron (import/export) was studied in gut mucosa, mainly by duodenal 
membrane binding protein divalent metal protein 1 (DMT1) and FPN [42–44]. How these 
proteins regulate iron import and export in the brain parenchyma is still unclear. For 
validation of DMT1 and FPN in the gut mucosa and other endothelial cells, tissue sections 
from mouse duodenum and choroid plexus (CP) were stained by IFC using anti-DMT1 
and anti-FPN antibodies. The most distinct feature of the small intestine is the mucosal 
lining, with brush border villi and crypts, lined with columnar cells. DMT1 staining was 
seen in the columnar cells within the crypts, particularly in the apical surface (Figure 4A) 
and FPN at the basolateral site and in the central core of lamina propria containing blood 
vessels (Figure 4B, C). These proteins are involved in absorbing iron from the luminal 
surface and transporting to the blood at the abluminal site via FPN (Figure 4A–C). 
As we previously reported, the CP is damaged in DS and AD brains, and CP is a 
conduit between the peripheral circulation and central nervous system via the 
cerebrospinal fluid [61,66]. We extended our investigation to CP sections from mouse 
brain (Figure 4D–F) and human brain, and stained with DMT1, FPN and hepcidin (Figure 
4G–I). DMT1 expressed in the monolayer of the epithelial cells of CP on the luminal sites, 
whereas FPN was found in the abluminal site of the CP with some co-localisation (Figure 
4D–F). Similarly, in the human brain, hepcidin was visible in the epithelial cells of CP, 
whereas FPN was seen in the macrophages very close to CP (Figure 4G–I). These findings 
suggest that hepcidin might be transported via exosomes or other small vesicles and FPN 
via macrophages to the brain parenchyma. Further, hepcidin and FPN are both visible in 
the oligodendrocytes located in the corpus callosum (CC), suggesting that iron transport 
may take place in the CC (Figure 4J–L). Both proteins are transported via blood vessels 
(Figure 4M,N). Other brain sections from cortices close to SP were stained with SOD1 
antibody, and very strong SOD1 protein staining was seen in the plaques and in the 
peripheral neurons (Figure 4O), indicating a mechanism of ROS scavenging in plaques of 
DS brain. To evaluate the role of SOD1 in the neurons and particularly in mitochondrial 
metabolism, we have to further explore it at a cellular level and in the serum. 




Figure 4. DMT1, FPN and hepcidin regulate endothelial transport and SOD1 modulates redox balance in DS brain. 
Tissue sections from mouse duodenum and choroid plexus (CP) were stained by IF using anti-DMT1 and anti-FPN 
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antibodies and counterstained with DAPI for nuclei (blue). In duodenum, DMT1 staining was seen in the columnar cells 
within the crypts, particularly in the apical surface (A) and FPN at the basolateral site and in the central core of lamina 
propria containing blood vessels (B,C). The choroid plexus (CP) sections from mouse brain (D–F) stained with DMT1 were 
expressed in the monolayer of the epithelial cells of CP on luminal sites, whereas FPN was found in the abluminal site of 
CP, with some co-localisation observed (D–F). Similarly, for human CP when stained with hepcidin and FPN antibodies, 
hepcidin was visible in the epithelial cells of CP and FPN was seen in the macrophages very close to CP (G–I). Hepcidin 
and FPN are both visible in the oligodendrocytes located in the corpus callosum (CC), suggesting that iron transport may 
take place through CC (J–L). Hepcidin and FPN were visible in the blood vessels (M,N). A brain section from the cortex 
close to a SP was stained with SOD1 antibody, and very strong SOD1protein was seen in the plaque and in the peripheral 
neurons (O). Scale bar: (A–F) = 20 μm, (G–L) = 25 μm, (M) = 50 μm, (N,O) = 20 μm. 
3.5. Inflammatory Changes in the DS Brain Were Identified by TREM2, IL-1β and IL-6 
Hepcidin and TREM2 could be involved in microglial activity and in the amyloid 
clearance process [38,53]. To assess this aspect, we extended our investigation to include 
hepcidin and TREM2 expression in microglia in control and DS brain samples (n = 10 from 
each group, Table 1), with a particular focus on identifying TREM2 expression in the Iba1-
positive microglia. The brain sections from DS and control subjects were stained with 
microglia marker (Iba1) and TREM2. In control brains, Iba1-positive ramified microglia 
were visible in the cortex, whereas TREM2 was noticed in the neurons close to the blood 
vessels (Figure 5A). There was expression of TREM2 in some cells but not in Iba1-positive 
microglia (Figure 5A). Similarly, in the DS brain, activated microglia were visible around 
the SP with limited co-localisation with TREM2 in the microglia (Figure 5B). In sections 
from the HP and DG of another DS brain where most of the granule cells were damaged, 
when stained with Iba1 and TREM2, Iba1-positive activated microglia were present close 
to the neurons, whereas TREM2 expression was visible only in the damaged DG granule 
cells with limited co-localisation (Figure 5C,D). These findings indicate that there are 
different populations of microglia sub-types present in the human brain. We further 
investigated white matter (WM) close to the blood vessels (BV) in the DS brain and found 
large numbers of Iba1-positive microglia, close to the blood vessels, that could be involved 
in the clearing process of damaged oligodendrocytes, and some TREM2-positive 
macrophages also seem to have entered from blood vessels (Figure 5E). For another DS 
brain including BV, when stained with hepcidin and IL-6, the staining pattern suggested 
that both proteins might be entering from the blood vessels (Figure 5F). 
To evaluate the effects of inflammatory changes in different glial cells, brain sections 
from controls and DS (cortex) subjects were stained with TREM2 and pro-inflammatory 
marker IL-1β. In control brain sections, TREM2 was visible in the neurons and in other 
cell types, and only very faint IL-1β expression was seen with limited co-localisation in 
the cell bodies (Figure 5G–I). In DS brain, however, very strong TREM2 expression, 
particularly in the neuronal cells, was observed, whereas IL-1β was noticed in the 
microglia, close to the blood vessels and with some co-localisation noted (Figure 5J–L). 
Similarly, control and DS brain sections, when stained with hepcidin and IL-6, showed 
that both the proteins were present in the cells close to the blood vessels and with some 
co-localisation (Figure 5M). In contrast, in the DS brain, damaged neurons with a halo 
around the nucleus were positive for hepcidin, and IL-6 was visible in the microglia 
(Figure 5N,O). These findings indicate that inflammatory cytokines enter in the brain 
parenchyma through the blood vessels. TREM2 is an anti-inflammatory protein that did 
not co-localise with Iba1-positive activated microglia, supporting our previous findings 
[65]. 




Figure 5. Inflammatory changes in the DS brain were identified by TREM2, IL-1β and IL-6. To investigate the 
inflammatory changes in DS, the brain sections from DS and control subjects were stained with microglia marker (Iba1) 
and TREM2. In control brains, Iba1-positive ramified microglia were visible in the cortex, whereas TREM2 was noticed in 
the neurons close to the blood vessels (A). In the DS brain sections, activated microglia was visible around the SP and 
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limited co-localisation with TREM2 in the microglia (B). For sections from the HP and DG of DS brain when stained with 
Iba1 and TREM2, Iba1-positive activated microglia were present close to the neurons, whereas TREM2 expression was 
visible only in the damaged DG granule cells with limited co-localisation (C,D). The white matter (WM) close to the blood 
vessels (BV) in the DS brain showed large numbers of Iba1-positive microglia, close to the blood vessels, that might be 
involved in the clearing process of damaged oligodendrocytes, and TREM2-positive macrophages might be entering from 
blood vessels (E). For another DS brain section, close to the BV, when stained with hepcidin and IL-6, the staining patterns 
suggested that both proteins might be entering from the blood vessels (F). The brain sections from controls and DS subjects 
(from cortex) were stained with TREM2 and pro-inflammatory marker IL-1β. In control, TREM2 was visible in the neurons 
(G) and in other glial cells, and only very faint IL-1β expression was seen (H), with limited co-localisation in the cell bodies 
(I). In DS brain, TREM2 expression was seen in the neurons, whereas IL-1β was noticed in the microglia, close to the blood 
vessels and with some co-localisation noted (J–L). Similarly, for control and DS brain sections, when stained with hepcidin 
and IL-6, both the proteins were present in the cells close to the blood vessels and with some co-localisation (M), whereas 
in the DS brain, damaged neurons with a halo around the nucleus were positive for hepcidin (N), and IL-6 was visible in 
the microglia (N,O). Scale bar: (A–C) = 50 μm, (D–F) = 30 μm, (G–O) = 20 μm. 
3.6. OLIG2 Defect Impairs Myelination in DS Brain 
We previously reported that WMT defects were seen in DS brain. Additionally, we 
have shown that in the rat brain, hepcidin and FPN were expressed in the white matter 
tract (WMT) of the corpus callosum (CC) and are involved in myelination [38,53,66]. 
OLIG2 promotes the formation and maturation of oligodendrocytes within the brain [70]. 
We investigated OLIG2 and myelin basic protein (MBP) expression in control and DS 
white matter (WM) in the cortex and in the basal ganglia (BG). In the control brain, MBP 
expression was seen in the myelinated sheath of oligodendrocytes, with OLIG2 localising 
in the cell bodies (Figure 6A–C), and in the DS brain, myelin sheaths appeared shrunken 
and damaged (Figure 6D–F). In some cases of DS brain, Aβ42-positive SPs were visible in 
the WM of the cortex (Figure 6G). In another DS brain section from BG, when stained with 
hepcidin and S100β, both proteins were seen in the WM. S100β, in particular, was present 
in the oligodendrocytes (Figure 6H,I), whereas hepcidin was seen in the wall of blood 
vessels (Figure 6I). In control brain, particularly in the BG, MBP and OLIG2 were positive 
in WMT (Figure 6J,K), whereas, in DS brain, Aβ42-positive SP were visible (Figure 6L). 
These findings indicated that triplication of OLIG2 may disturb the myelination process 
in DS. 




Figure 6. OLIG2 defect impairs myelination in DS brain. For DS and control white matter (WM) in the cortex and in the 
basal ganglia (BG), OLIG2 and myelin basic protein (MBP) expression were analysed by IF and counterstained with DAPI 
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for nuclei (blue). In the control brain, MBP expression was seen in the myelinated sheath of oligodendrocytes, with OLIG2 
localising in the cell bodies (A–C), and in the DS brain, myelin sheaths appeared to be shrunken and damaged (D–F). In 
DS brain, Aβ42-positive SPs were visible in the WM of the cortex (G). For another DS brain section from BG, when stained 
with hepcidin and S100β, both proteins were seen in the WM, and in particular, S100β was present in the oligodendrocytes 
(I), in astrocytes (H,I), whereas hepcidin was seen in the blood vessels walls (H,I). In control brain, particularly in the BG, 
both proteins, MBP and OLIG2, were seen in WMT (J,K), whereas, in DS brain, Aβ42-positive SPs were visible (L). Scale 
bar: (A–F) = 20 μm, (G–L) = 30 μm. 
3.7. Serum Hepcidin and IL-6 Could Be Involved in Host Defence Mechanism in DS Brain 
To investigate the effect of trisomy-21-related proteins (Aβ42, SOD1, S100β) and iron 
regulatory proteins (FTL, FPN, hepcidin), as well as inflammatory marker TREM2, on 
serum levels, a cohort of DS subjects (n = 18) and age-matched controls (n = 18) was 
analysed by Western blotting. Aβ42 (4 kDA) and S100β (11 kDA) levels were higher in the 
DS subjects compared to the controls (Aβ42, p < 0.084, S100β p < 0.26, paired t-test, not 
significant) (Figure 7A and Supplementary Table S1). In contrast, SOD1 (18 kDA) level 
was found to be very high in DS serum (R2 = 0.64, p < 0.0001, Supplementary Table S1). 
However, FTL (19 kDA), FPN (69 kDA) and TREM2 (25 kDA) were significantly decreased 
in the DS serum (p < 0.0001, p < 0.003 and p < 0.002 respectively, Supplementary Table S1). 
By contrast, hepcidin was significantly higher in DS serum (p < 0.001) (Figure 7A, 
Supplementary Table S1). 
Due to the large number of serum samples and the heterogeneity of different batches 
of blots generated by WB analysis, we decided to further analyse using ELISA, with 
reliable kits available for the tests. We investigated serum ferritin, hepcidin, TREM2 and 
IL6 levels in ‘young DS’ (YDS, n = 23, 30–45 years) and ‘older DS’ (ODS, n = 24, 46–70 
years) participants and then compared them with age-matched controls (young, YC, and 
old, OC, n = 25 in each group) using sandwich ELISA. All samples were analysed on the 
same day, using the same standardised protocol to reduce the day-to-day variations. 
Serum iron was measured by clinical biochemistry, at the Addenbrooke’s Hospital of 
Cambridge University NHS Foundation Trust located in Cambridge, UK, as described in 
our previous publication [39]. Serum iron levels were significantly higher (p < 0.001) in 
young controls (YC, 25.07 ± 5.06 μmol/L) and in old controls (OC, 20.18 ± 7.2 μmol/L) 
compared to young DS (YDS, 19.11 ± 4.5 μmol/L) and old DS (ODS, 13.92 ± 7.4 μmol/L). 
ELISA data were evaluated (in four groups) by nonparametric statistical analysis 
(Kruskal–Wallis and post hoc with Mann–Whitney U test, R2 0.49, p < 0.0001, Table 2). 
Hepcidin levels were substantially higher in DS (YDS, mean ± SD: 376.36 ± 475.4 
μg/L), and ODS, 241.02 ± 430.5 μg/L) compared to both young and old controls (YC, 23.89 
± 19.1 μg/L, and OC, 26.56 ± 16.1 μg/L, R2 0.35, p < 0.0001, Figure 7B). All data were 
analysed using one-way ANOVA, which compared between groups, followed by 
Kruskal–Wallis or Bartlett’s tests, corrected (Table 2), and paired t-tests, between YC vs. 
YDS and YC vs. OC, as shown in Supplementary Table S1. Similarly, serum ferritin was 
highest in controls (YC, 216.9 ± 171.1 μg/L, and OC, 211.43 ± 45.5 μg/L, Supplementary 
Table S1), and lowest in the young DS (YDS, 122.56 ± 10.4 μg/L, compared to ODS, 139.83 
± 85.7 μg/L) (Figure 7C, one-way ANOVA, R2 0.31, p < 0.0001, Table 2). Serum TREM2 
levels were the highest in young controls (YC, 1190.91 ± 150.2 pg/mL, and OC, 796.26 ± 
147.65 pg/mL) and the lowest in the old DS (YDS, 894.30 ± 201.52 pg/mL, and ODS, 562.79 
± 112.75 pg/mL, R2 0.48, p < 0.0001) (Figure 7D, Table 2). Serum IL-6 was higher in DS 
(YDS, 244.29 ± 144.4 μg/L, and ODS, 343.14 ± 320.1 μg/L) compared to both controls (YC, 
52.62 ± 21.01 μg/L, and OC, 76.55 ± 31.4 μg/L, R2 0.63, p < 0.0001) (Figure 7E). Serum 
hepcidin and IL-6 levels were both highest in the old DS subjects (R2 0.47, p < 0.0001, Figure 
7F,G, Table 2). In contrast, serum TREM2 was higher in the controls compared to DS 
participants (R2 0.77, p < 0.0001, Figure 7H, Table 2). These findings suggest that serum 
hepcidin and IL-6 could be involved in host defence mechanisms seen in 
neuroinflammation. 




Figure 7. Serum hepcidin and IL-6 could be involved in host defence mechanism in DS brain. RUNX1 mRNA 
expression was higher in the liver, bone marrow and duodenal endothelial cells, as assessed by in situ hybridisation. To 
investigate the effect of trisomy-21-related proteins (Aβ42, SOD1, S100β) and iron regulatory proteins (FTL, FPN, 
hepcidin), as well as inflammatory marker TREM2, on serum levels, a cohort of DS subjects (n = 18) and age-matched 
controls (n = 18) was analysed by Western blotting. Aβ42 (4 kDA) and S100β (11 kDA) levels were higher in the DS subjects 
compared to controls (Aβ42, p < 0.084, S100β p < 0.26, paired t-test, not significant) (Figure 7A and Supplementary Table 
S1). In contrast, SOD1 (18 kDA) level was found to be very high in DS serum (R2 = 0.64, p < 0.0007). However, FTL (19 
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kDA), FPN (69 kDA) and TREM2 (25 kDA) were significantly decreased in DS serum (p < 0.0001, p < 0.003 and p < 0.002, 
respectively) (Supplementary Table S1). Serum hepcidin was significantly higher in DS serum (p < 0.001) (A). Human 
serum from young and old DS (YDS, n = 23, and ODS, n = 24) and age-matched young and old control subjects (YC and 
OC, n = 25 in each group) were analysed by ELISA. Scattered plot showing the levels of serum hepcidin (B), ferritin (C), 
TREM2 (D) and IL-6 (E) (methods described in the main text and results were analysed by using one-way ANOVA that 
compared between groups, followed by Kruskal–Wallis or Bartlett’s test, corrected (Table 2), and a paired t-test, between 
YC vs. YDS and YC vs. OC, as shown in Supplementary Table S1). Serum ferritin was highest in controls (YC, 216.9 ± 171.1 
μg/L, and OC, 211.43 ± 45.5μg/L) and lowest in the young DS (YDS, 122.56 ± 10.4 μg/L, compared to ODS, 139.83 ± 85.7 
μg/L) (Figure 7C, R2 0.31, p < 0.0001, Table 2). Serum TREM2 levels were the highest in young controls (YC, 1190.91 ± 150.2 
pg/mL, and OC, 796.26 ± 147.65 pg/mL) and the lowest in the old DS (YDS, 894.30 ± 201.52 pg/mL, and ODS, 562.79 ± 
112.75 pg/mL, R2 0.48, p < 0.0001) (Figure 7D, Table 2). Serum IL-6 was higher in DS (YDS, 244.29 ± 144.4 μg/L, and ODS, 
343.14 ± 320.1 μg/L) compared to both controls (YC, 52.62 ± 21.01 μg/L, and OC, 76.55 ± 31.4 μg/L, R2 0.63, p < 0.0001) (E). 
Serum hepcidin and IL-6 levels were both highest in the old DS subjects (R2 0.47, p < 0.0001 (F,G), Table 2). In contrast, 
serum TREM2 was higher in the controls compared to DS participants (R2 0.77, p < 0.0001 (H), Table 2). Statistical 
differences were calculated by Mann–Whitney U test. *** p < 0.001 and **** p < 0.0001. The RUNX1 mRNA expression 
pattern by RT-PCR, in wild-type mouse (C57/bl6) tissues from different tissues, is shown in the I. This analysis revealed 
low levels of mRNA in the brain with a slightly higher signal observed in the heart, skeletal muscle, gut, liver and with 
the highest expression seen in the bone marrow and peripheral mononuclear leukocytes (PBMC) (I). To identify cellular 
levels, tissues sections from embryonic (ED16) and adult mice were analysed by in situ hybridisation (ISH). Very high 
mRNA was visible in ED16 mouse brain, throughout the cortex and in the brain cavity (J), but less in the adult brain, being 
only visible in the HP and DG (K), and clearly in the brain blood vessels (in the blood cells) (L). However, higher mRNA 
expression was seen in the bone marrow, endothelial layer of the heart and duodenum (M,N,P). The highest mRNA level 
was seen in the liver (O). Adult spleen sections were hybridised with ferritin as a control probe, and strong mRNA was 
visible (Q). We analysed by IF, using RUNX1 and hepcidin antibodies and counterstained with DAPI for nuclei (blue). 
Both proteins were observed in the embryonic brain, in the ED16 body and spinal cord (R–T), with co-localisation in the 
epithelial cells of the placenta (U). RUNX1 was distinctly visible in the embryonic liver (V), endothelial cells of the gut and 
in the muscles (W,X), and co-localised with hepcidin in the adult liver hepatocytes (Y). Scale bar: (H,K–L) = 30 μm, (I,J) = 
50 μm (M–O) = 100 μm, (P–Y) = 25 μm. 
Table 2. Characteristics of DS and age-matched control study population used to measure serum iron, ferritin, hepcidine, 















Male + Females N = 25 N = 23 N = 25 N = 24 F (DFn, DFd)    
Age (years) 40 ± 10 30 ± 10 50 ± 27 41 ± 25     
Iron Parameter         
Serum iron 
(μmol/L) 
25.07 ± 5.06 19.11 ± 4.5 20.18 ± 7.2 13.92 ± 7.4 32.47 0.4985 p < 0.0001 **** 
Serum Ferritin 
(μg/L) 
216.9 ± 171.1 122.56 ± 10.4 211.43 ± 45.5 139.83 ± 85.7 13.64 0.3198 p < 0.0001 **** 
Serum Hepcidin 
(μg/L) 
23.89 ± 19.1 376.36 ± 475.4 26.56 ± 16.1 241.02 ± 430.5 18.09 0.35 p < 0.0001 **** 
Inflammatory 
Parameter 
        
Serum IL-6 
(μg/L) 
52.62 ± 21.01 244.29 ± 144.4 76.55 ± 31.4 343.14 ± 320.1 55.78 0.6307 p < 0.0001 **** 
SerumTREM2 
(pg/mL) 
1190.91 ± 150.2 894.30 ± 201.52 796.26 ± 147.65 562.79 ± 112.75 22.22 0.4807 p < 0.0001 **** 
Data are expressed as number of patients, mean  SD. Probability values (p) denote differences between control and DS 
groups. One-way ANOVA that compared between groups, followed by Kruskal–Wallis or Bartlett’s test (corrected), was 
used that compared to age between groups, followed by Mann–Whitney test. **** p < 0.0001. 
3.8. RUNX1 mRNA Expression Was Higher in the Liver, Bone Marrow and Duodenal 
Endothelial Cells, as Assessed by In Situ Hybridisation (Evaluated in Mouse) 
The runt-related transcription factor RUNX1 gene is located in human chromosome 
21 and is highly conserved in many species, including humans and mice. Mutations and 
translocations in the RUNX1 gene are frequently seen in acute myeloid leukaemia (AML), 
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myelodysplastic syndromes (MDS) and other forms of haematological malignancies 
common among DS subjects [71]. Therefore, we validated the RUNX1 mRNA expression 
pattern by RT-PCR, in wild-type mouse (C57/bl6) tissues from ED16 body, brain (cortex), 
heart, muscles, duodenum, liver, bone marrow and peripheral leukocytes (Figure 7G). 
This analysis revealed low levels of mRNA in the brain, with a slightly higher signal 
observed in the heart, skeletal muscle, gut, liver and with the highest expression seen in 
the bone marrow and peripheral mononuclear leukocytes (PBMC) (Figure 7I). 
To investigate differential distribution of mRNA in different organs, we extended 
our findings to cellular levels by in situ hybridisation (ISH) using a RUNX1 probe (320 
base pairs) amplified by DIG labelling, and freshly frozen mouse tissues from liver, brain, 
duodenum and embryonic body (ED16) were analysed. Very high mRNA levels were 
visible in ED16 mouse brain, throughout the cortex and brain cavity (Figure 7J), but less 
in the adult brain, where they were only visible in the HP and DG and clearly in the brain 
(Figure 7J,K) and in the blood vessels (in the blood cells) (Figure 7L). However, higher 
mRNA expression was seen in the bone marrow, endothelial layer of the heart and 
duodenum (Figure 7M,N,P). The highest mRNA level was seen in the liver (Figure 7O). 
When another spleen section was hybridised with control probe (ferritin), strong mRNA 
was visible (Figure 7Q). Taken together, these in situ data suggest that RUNX1 is 
transcribed in the liver, bone marrow and endothelium of the blood vessels, and could be 
the likely explanation of the higher signal seen with RT-PCR. 
We stained ED16 mouse brain with RUNX1 and hepcidin antibodies. Both proteins 
were observed in the embryonic brain, in the ED16 body and spinal cord (Figure 7R–T), 
with co-localisation in the epithelial cells of the placenta (Figure 7U). RUNX1 was 
distinctly visible in the embryonic liver (Figure 7V), endothelial cells of the gut and in the 
muscles (Figure 7W,X), and co-localised with hepcidin in the adult liver hepatocytes 
(Figure 7Y). These data suggests that RUNX1 protein highly expresses in the embryonic 
stages and in adult stages, particularly in those cells that have self-renewal properties. 
3.9. RUNX1 and Hepcidin Were Observed in the Erythro-Megakaryocytes and Platelets, 
Suggesting a Myeloid Origin 
RUNX1 affects crucial processes such as self-renewal of haematopoietic stem cells 
and differentiation of the myeloid and lymphoid cell lineages [24]. There is an increased 
risk of leukaemia in adults with DS, and a variety of haematological abnormalities, 
including abnormal erythrocytosis, macrocytosis and leukopenia are also seen [71]. 
Therefore, we analysed RUNX1 and hepcidin expression in blood smears from DS 
participants (n = 20, from different age groups between 30 and 65 years) and age-matched 
controls and then imaged them with confocal microscopy. DS and control blood smears 
were co-labelled with RUNX1 or hepcidin and glycophorin, an erythrocyte plasma 
membrane-marker. Both proteins were found to co-localise in the RBC membranes, 
suggesting that RUNX1 expresses on the surface of RBCs (Figure 8A, Table 3). Hepcidin 
was observed within the cell bodies of RBCs and mononucleated cells (MNCs) in blood 
smears of a control subject (Figure 8B). In blood smears from young DS participants, 
abnormal RBCs and a classic dysmorphology (bi-lobed neutrophils) were frequently 
observed with very granular hepcidin in the RBC membranes (Figure 8C). In contrast, 
normal neutrophils positive for hepcidin (green) and platelet marker CD42b (red) were 
found in control smears (Figure 8D). The blood smear from a young DS participant (DS12, 
30 years old) showed more hepcidin protein expression within MNC and around the 
neutrophils, and a very limited number of CD42b-positive platelets was seen (Figure 8E). 
One older DS participant (DS28, 65 years old) showed very abnormally clumped RBCs 
and low platelet counts (Figure 8F), whereas another young DS participant (DS19, 32 years 
old) displayed soluble hepcidin around the MNCs, and Aβ42 was found scattered in the 
platelets (Figure 8G). Two young DS participants’ blood sample smears (DS18, aged 32 
years and DS55, aged 39 years, with the TREM2 R47H, C to T mutation), that showed 
abnormally shaped RBCs (Figure 8C) with abnormal accumulation of TREM2 around the 
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MNC (Figure 8I), were reported previously [29]. Another blood smear from a control 
participant when stained with glycophorin and TREM2 showed TREM2 being present 
around the RBC membrane (Figure 8H). To confirm that hepcidin and RUNX1 are 
expressed in human bone marrow megakaryocytes, two DS bone marrow slides were 
stained with RUNX1, hepcidin and FPN. Both proteins were expressed in the bone 
marrow blast cells and co-localised where FPN was expressed in RBCs (Figure 8J,K, Table 
3). These findings indicate that RUNX1 protein is crucial for processes such as the self-
renewal of haematopoietic stem cells and differentiation of the myeloid and lymphoid cell 
lineages, whereas hepcidin may be essential for normal development of RBCs and 
platelets, as well as transporting soluble proteins. TREM2 mutation causes Aβ42 
accumulation in the erythrocytes, as we reported previously [29]. 
Table 3. Characterisation of blood smears of Down syndrome and normal control subjects. 
Cell Types 
Controls 










Young (YC), n = 
10 (age 30–40 
years) 
Old (OC), n = 
10 (age 41–65 
years) 
 
Young (YDS), n = 
10 (age 30–40 
years) 
Old (ODS), n = 10 
(age 41–65 years) 
All older DS participants 
developed Alzheimer’s 







paler zone in 
the centre 
(Figure 8B). 
Staining is more 
intense at the 
periphery. 






hypochromic blood film 
was seen in old DS 
subjects (Figure 8F) 
Neutrophils Normal Normal 
The cytoplasm is 
pale pink and 
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of coarse chromatin. 
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segmented. 
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with large eosinophilic 
granules 
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Found in two cases who 
had hypothyroidism.  








The nucleus was an 
irregular shape. 
Monocytes Normal Normal 
Large cells, the 












often with nucleoli 
(Figure 8G). 
Some of the monocytes 
were activated T cells. 
(Figure 8C,F) 
Platelets Normal Normal 
Platelets were 
round or oval and 
had an irregular 
outline (Figure 
8D). 
Platelet count was 
very low (Figure 
8E) 
Platelet count was 
reduced, and cell 
fragmentation was 
visible (Figure 8F). 
Low platelet count is 
common in young DS, 
who are prone to suffer 
from acute myeloid 
leukaemia (AML). 
Bone marrow Not analysed Not analysed Not analysed 
The 
proerythroblast 
was seen, large 





Bone marrow (BM) was 
hypercellular with gross 
myeloid hyperplasia. The 
cytoplasm was dense and 
there was often a 
perinuclear pale zone 
(Figure 8K). 
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of soluble TREM2 
around the MNCs. 
TREM2 mutation 
impaired trafficking of 
TREM2 to the plasma 
membrane of 
erythrocytes in DS, which 
could affect amyloid 
clearance from blood cells 
[29]. 
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blood smears. 




Aβ42 was visible 
in in abnormal 
shape RBCs and 
co-localised in 
platelets (very low 
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(Figure 8F). 
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CD42b is a platelet 
marker 
Platelet count was 
very low (Figure 
8E). 
Platelet count was 
reduced, and cell 
fragmentation was 
visible (Figure 8F) 
Low platelet count is also 
seen in acute myeloblastic 
leukaemia, which was 
seen in one young DS. 




Figure 8. RUNX1 and hepcidin were observed in the erythro-megakaryocytes and platelets, suggesting a myeloid 
origin. We analysed RUNX1 and hepcidin expression in blood smears from DS subjects (n = 20) and age-matched controls 
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(n = 20) and then imaged with confocal microscopy. DS and control blood smears were co-labelled with RUNX1 or 
hepcidin and glycophorin, an erythrocyte plasma membrane-marker. Both proteins (RUNX1 and glycophorin) were found 
to co-localise in the RBC membranes, suggesting that RUNX1 expressed on the surface of RBCs (A). Similarly, another 
smear from control and DS was stained with hepcidin and glycophorin. In control subjects, hepcidin was observed 
scattered, extra-corporally to RBCs and within the cell bodies of mononucleated cells (MNCs) (B). In young DS blood 
smears, a classic dysmorphology (bi-lobed neutrophils) with significantly higher hepcidin protein around the MNCs was 
frequently observed (C,E), whereas normal neutrophils positive for hepcidin (green) and platelet marker CD42b (red) 
were found in controls smears (D). The blood smear from a young DS subject (DS12) showed more hepcidin protein 
expression within MNC and around the neutrophils, and a limited number of CD42b-positive platelets was seen (E). One 
old DS subject (DS28) showed very abnormal clumped RBCs and low platelet counts (F), whereas another young DS 
(DS19) displayed soluble hepcidin around the MNCs, and Aβ42 was found scattered in the platelets (G). Two young DS 
participants’ blood sample smears (DS18, aged 32 years, and DS55, aged 39 years, with the TREM2 R47H, T mutation) 
showed abnormally shaped RBCs in their smears (C), with abnormal accumulation of TREM2 around the MNC (I), as 
reported in our previous publication [29]. A blood smear from a control participant was stained with glycophorin and 
TREM2, showing TREM2 being present around the RBC membrane (H). To confirm that hepcidin and RUNX1 are 
expressed in human bone marrow megakaryocytes, two DS bone marrow slides were stained with RUNX1, hepcidin and 
FPN. Both proteins were expressed in the bone marrow blast cells and co-localised where FPN expressed in RBCs (J,K). 
These findings indicate that RUNX1 protein is crucial for processes such as the self-renewal of haematopoietic stem cells 
and differentiation of the myeloid and lymphoid cell lineages, whereas hepcidin may be essential for normal development 
of RBCs and platelets, as well as transporting soluble proteins (Table 3). Scale bar: (A–I) = 20 μm, (J,K) = 10 μm. 
4. Discussion 
Down syndrome (DS) is characterised by progressive age-related cognitive and 
functional impairment associated with memory loss and premature ageing [3,28,29]. 
There are many factors involved in the neuropathology of AD dementia (ADD) in DS that 
contribute significantly towards the pathophysiology and enhanced ageing processes. The 
mechanism behind the early onset of AD pathology is not fully understood, but in this 
paper, we report that the overexpression of certain genes on chromosome 21, particularly 
in the Down syndrome critical region 1 (DSCR1) that includes APP, Cu/Zn superoxide 
dismutase (SOD1), S100β and RUNX1 transcription factors, play crucial roles [2]. It has 
been hypothesised that changes in gene expression in chromosome 21 are likely to affect 
the expression of genes on other chromosomes through the modulation of transcription 
factors, immune regulation and other factors [7,11,17]. 
This study was aimed at determining how the overexpression of genes in triosomy-
21 (i.e., APP, S100β, SOD1 and RUNX1) and other disomic genes affects (possibly via 
amyloid protein transport and clearance) neuroinflammation and accelerates ageing. 
Although dysfunction of APP processing is believed to be the key upstream factor in the 
pathogenesis of AD [55], neuroinflammation and activation of innate immunity are 
considered early events in the genesis of AD and in DS dementia [72]. In DS and in LOAD, 
neuroinflammation has been linked to the exacerbation of both SP and NFT pathology, as 
well as the clearance of Aβ from amyloid plaques [56–58]. We therefore characterised the 
senile plaque (SP) formation and glial cell defects in DS. Plaque pathology was quite 
different between the young and old DS brains. In a younger (42 years old) DS brain, 
abundant cotton wool appearance of SPs, composed of Aβ42, was seen throughout the 
cortex (Figure 1A). Most of the plaques were formed from a cluster of small swollen 
neurites surrounded by neuropil without an amyloid core, whereas in the periphery, some 
other mature SPs were surrounded by a halo of Aβ42 (Figure 1A). The SPs were composed 
of GFAP-positive astrocytes, and the end-feet of astrocytes surrounded the endothelial 
layer of blood vessels. It is likely that end-feet of astrocytes could import nutrients to brain 
parenchyma and export lipid and waste products to the blood vessels [73]. These findings 
support the notion that not only neurons but also astrocytes contribute a great deal in 
amyloid clearance and plaque formation. 
There are many genes triplicated on Hsa21, particularly Cu/Zn superoxide dismutase 
(SOD1) and S100β, which are associated with oxidative stress, and their overexpression 
may contribute to a genetic imbalance in DS that potentiates the development of ROS 
[12,35]. S100β is a member of the EF-hand type of calcium binding S100 protein family 
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found in the brain and triplicated in the DSCR1 region [74]. Under normal physiological 
states, S100β is expressed predominantly in the astroglia, and also to a lesser extent in the 
neurons, microglia and oligodendrocytes [69]. S100β promotes neurotransmitter 
development and maturation in the mammalian brain, and it has a role in the cascade of 
glial changes associated with neuroinflammation [69]. We analysed DS and age-matched 
controls with the S100β antibody by IF. In control brain, S100β-positive normal astrocytes 
with thin filamentous processes of end-feet were present and surrounding the blood 
vessels (Figure 2J–L). Whereas, in DS brain, when S100β-positive, the end-feet of 
astrocytes were damaged, disorganised and aggregated around the wall of blood vessels, 
indicating changes to the cytoskeleton and altered astroglial morphology (Figure 2M–O). 
Within astroglial cells, S100β regulates Ca2+ levels, and once activated by Ca2+, S100β 
interacts with intermediate filaments including GFAP and vimentin and might have a role 
in ageing and neuropathology of DS [74]. It was also described that overexpression of 
human S100β exacerbates cerebral amyloidosis and gliosis in the mouse model of 
Alzheimer’s disease [75]. Our findings support that S100β might be involved in amyloid 
clearance from astrocytes, and due to the failure of transport, may lead to SP formation. 
This could be one factor of premature signs of ageing and reactive gliosis in DS. 
Another protein that is triplicated in the DSCR1 region is superoxide dismutase 1 
(SOD1). To cope with this natural source of ROS, it is equipped with a sophisticated 
antioxidant defence system which counteracts and controls ROS levels to maintain 
physiological homeostasis [76]. Superoxide dismutases (SODs) are a class of enzymes that 
catalyse the conversion of superoxide radicals to oxygen and hydrogen peroxide. SOD 
activity relies on a specific catalytic metal ion, which could be manganese (MnSOD), iron 
(FeSOD), nickel (NiSOD) or copper (Cu/ZnSOD) [77]. It is commonly known for its 
scavenging activity of ROS, but recent work has uncovered additional roles in modulating 
metabolism, maintaining redox balance and regulating activation of nuclear gene 
transcription following exposure to oxidative stress [78]. The impairment of SOD1 
antioxidant function or the toxic gain of function have been associated with diseases, 
including DS [79]. We have seen a significant upregulation of SOD1 in the DS serum and 
high SOD1 staining, particularly in the neurons in senile plaque (Figure 4O). This 
observation requires further evaluation in larger samples to ascertain the role of SOD1 in 
DS. 
Iron proteins (ferritin, hepcidin, FPN and DMT1) are involved in inflammation 
[38,41,48,55]. Hepcidin is a key regulatory protein of iron homeostasis, and due to its size 
(2.8 kDA), it could easily transport iron from periphery to the brain parenchyma [38]. In 
DS brain, hepcidin was present in the activated astrocytes around the SP and in the 
endothelial cells of the blood vessels, indicating that hepcidin is involved in glial iron 
transport from astrocytes to the blood vessels [38]. We reported that hepcidin is present 
in the end-feet of astrocytes that surround the blood vessels and is involved in iron 
transport [39]. Additionally, we reported that the choroid plexus (CP) is damaged in DS 
and AD brains and CP is a conduit between the peripheral circulation and central nervous 
system via the cerebrospinal fluid [66]. Here, we showed that, in mouse brain, DMT1 is 
expressed in the monolayer of epithelial cells of CP on luminal sites, whereas FPN was 
found in the abluminal site of CP as well as in the macrophages very close to the epithelial 
cells of CP. Similarly, in human brain, hepcidin was visible in small vesicles in the 
epithelial cells of CP. These results support our previous findings of hepcidin being 
transported through exosomes or other small vesicles, while FPN is transported via 
macrophages to the brain parenchyma [39]. 
Hepcidin and ferroportin are expressed in the oligodendrocytes of WMT. We 
previously reported that WMT defects were seen in DS brain white matter (WM), and, in 
the rat brain, hepcidin and FPN expressed in the WMT of the corpus callosum (CC) and 
were involved in myelination [53,66]. Hepcidin and FPN could be involved in glial 
activities not only in astrocytes but also in the oligodendrocytes to transport amyloid and 
other proteins [38]. To assess this aspect, we extended our investigation to evaluating 
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hepcidin and FPN in WM in controls and DS brains. Hepcidin staining was visible in the 
WM, with normal appearance in the control brain. Contrastingly, very granular 
appearance was noticed in the cell bodies of oligodendrocytes in the DS brain. Hepcidin 
was also present in the WMT of basal ganglia (BG), with punctate accumulation of 
vesicular hepcidin in the cell bodies and around the blood vessels. It was reported that 
FPN could bind to APP in AD brain [54]. Here, we could show that both FPN and hepcidin 
have important roles in transporting amyloid and iron via WMT. 
OLIG1 and OLIG2 are oligodendrocyte proteins that triplicated in the DSCR 1 region 
in DS. Both these genes regulate multiple steps in the formation of neurons and astroglia 
within the CNS [80,81]. These proteins also promote the formation and maturation of 
oligodendrocytes within the brain [70]. We investigated OLIG2 and myelin basic protein 
(MBP) expression in control and DS white matter of the cortex and in the basal ganglia 
(BG). In the control brain, MBP expresses in the myelinated sheath of oligodendrocytes, 
and OLIG2 localised in the cell bodies, whereas in the DS brain, myelin sheaths were 
shrunken and damaged. These findings indicated that OLIG2 gene defect is also 
implicated in myelination defects in DS, and this impairment in white matter could be one 
of the factors for cortico-basal degeneration in DS. 
Abnormalities in the immune system are also seen in people with DS and can play a 
role in the pathogenesis of AD. Besides iron levels in the circulation, inflammation is yet 
another factor regulating hepcidin transcription in the hepatocytes. Inflammatory 
cytokines, IL-6 and IL-1β, are the main pathological mediators causing cytokine release 
[39,61]. Our serum analysis showed hepcidin and IL-6 levels to be significantly higher in 
the old DS participants but not in the young DS participants (p < 0.0001). Additionally, in 
the cortex of one participant with DS, hepcidin was present in damaged neurons with a 
halo around the nucleus, and IL-6 was visible in the microglia, suggestive of signs of 
nuclear damage and cell death with disease progression (Figure 5N). These findings 
indicate that both proteins, hepcidin and IL-6, are involved in host defence mechanisms 
during neuroinflammation, and failure results in cell death. 
The identification of a novel variant in the gene TREM2 has refocused attention on 
inflammation as a major contributing factor in AD. Genome-wide association studies have 
shown that a rare mutation of TREM2 (R47H, nucleotide C to T substitution) correlates 
with a heightened risk of developing AD [63,64,82]. In vitro studies indicate that TREM2 
deficiency reduces the efficacy of amyloid clearance [83] and thus can contribute to the 
pathogenesis of AD [63,65]. In our cohort, two young DS participant’s blood smears 
(DS18, aged 32 years, and DS55, aged 39 years, with the TREM2 R47H mutation) showed 
abnormally shaped RBCs in their smears with abnormal accumulation of TREM2 around 
the MNC (Figure 8C, I) [29]. Both DS subjects developed dementia within five years. 
We demonstrated impaired trafficking of TREM2 to the plasma membrane of erythrocytes 
in DS, which could affect amyloid clearance from blood cells [29]. 
RUNX1 protein is crucial in processes such as self-renewal of haematopoietic stem 
cells and differentiation of the myeloid and lymphoid cell lineages [24]. We analysed 
RUNX1 protein in DS and control blood smears that were co-labelled with hepcidin and 
an erythrocyte plasma membrane marker, glycophorin. Both proteins were found to be 
co-localised in the RBCs membranes, suggesting RUNX1 expression on the surface of 
RBCs (Figure 8A). Hepcidin was observed to be scattered and present extra-corporally to 
RBCs and within the cell bodies of mononucleated cells (MNC) in the blood smear of a 
control subject. In contrast, in blood smears from young DS participants, classic 
dysmorphology (bi-lobed neutrophils) with significantly higher hepcidin around the 
MNC was frequently observed. In control blood smears, hepcidin was present in 
neutrophils and platelets, whereas in DS, a very limited number of CD42b-positive 
platelets were seen. For two DS bone marrow slides, when stained for RUNX1 and 
hepcidin, both proteins expressed in bone marrow blast cells and co-localised. These 
findings indicated that RUNX1 protein is crucial for processes such as self-renewal of 
haematopoietic stem cells and differentiation of the myeloid and lymphoid cell lineages, 
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and that hepcidin may be essential for normal development of RBCs and for transporting 
soluble proteins. RUNX1 and hepcidin were observed in erythro-megakaryocytes and in 
platelets, suggesting a myeloid origin, and impairments of these proteins could cause 
myelodysplastic syndromes (MDS) and premature ageing of erythroid cells [29]. 
Hepcidin expression has been studied in many neurological disorders, including 
multiple sclerosis (MS), stroke, Parkinson’s disease (PD) and AD [38,84–86]. In a 
preliminary study of acute ischemic stroke (AIS), hepcidin levels were analysed and it was 
reported that plasma hepcidin levels were significantly higher in ischemic stroke patients 
compared with the control groups [84]. It was also mentioned that the hepcidin level 
significantly increased one week after diagnosis and after treatment with thrombolysis. 
This was an informative paper, but the authors did not explain why the hepcidin level 
increased or its importance in AIS [84]. Another group analysed serum hepcidin levels in 
multiple sclerosis (MS) in relapsing and progressive patients (active vs. inactive subjects, 
n = 71) and compared with healthy controls (n = 16) [85]. Serum hepcidin levels were 
significantly higher in MS participants (26.9 ng/mL) compared to (17.3 ng/mL) in healthy 
controls. The authors concluded that after correction for age and sex, the hepcidin 
difference was insignificant [85]. There are many unexplained questions in this study, and 
one of the important points is that hepcidin levels increased in the very early stages of 
inflammation, and it could be very different in MS (relapsing vs. progressive: active 
versus inactive stage) subjects. The disease duration was loo long, and that may affect the 
serum hepcidin production as well as the requirement to analyse a larger control group. 
The level of hepcidin in inflammatory diseases such as MS is very important and requires 
further research. Hepcidin protein may increase in early disease processes in other 
neurological disorders. Recently, another article reported higher serum pro-hepcidin 
levels in Parkinson’s disease (PD) after treatment of deep brain stimulation [86]. Hepcidin 
has immunomodulatory and neuroprotective effects, as we have seen in another ALS rat 
model, where after injury, hepcidin levels increased in new neurons, suggesting that 
hepcidin might increase in neurogenesis [87]. 
Our results strongly signify that DS pathology is multifactorial, and epigenetics and 
gene triplications influence many genes that not only cause neuronal but also extensive 
glial defects involving astrocytes and oligodendrocytes. These glial cells are essential for 
clearance of amyloid protein, and failure of such processes can lead to inflammation and 
cell death, as is observed in DS. 
5. Conclusions 
In Down syndrome, Aβ deposits begin to accumulate as early as in childhood and 
increase progressively with age. This is primarily due to the triplication of the DSCR1 
region on chromosome 21, where APP, S100β, SOD1, OLIG2 and RUNX1 genes are 
located. RUNX family transcription factors play critical roles in the development of neural 
and non-neural cells. RUNX1 protein is also crucial for processes such as self-renewal of 
haematopoietic stem cells and the differentiation of myeloid and lymphoid cell lineages. 
Hepcidin, however, may be essential for normal development of RBCs and for 
transporting soluble proteins. RUNX1 and hepcidin were observed in erythro-
megakaryocytes and in platelets, suggesting a myeloid origin of these proteins. SOD1 and 
S100β, on the other hand, have been associated with oxidative stress and ROS formation 
that could potentially lead to astrogliosis and neuroinflammation in DS. 
Various immunological and haematological abnormalities are developmental and 
are common in DS, suggesting that inflammation and activation of innate immunity are 
early events in DS that may play a role in the pathogenesis of AD. The iron regulatory 
genes, ferritin, FPN and hepcidin, are involved in glial iron transport from astrocytes to 
blood vessels, and impairment of this process also impacts neuroinflammation. Serum 
hepcidin and IL-6 could be involved in host defence mechanisms of neuroinflammation, 
as seen in PD [86]. The expression of TREM2 in myeloid cells, even in erythro-
megakaryocyte progenitors, strongly supports an intrinsic immune factor involvement in 
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ageing and abnormal cellular processes seen in DS. Soluble TREM2 protein carried by 
platelets and erythrocytes from the periphery enters the brain parenchyma via a subset of 
microglia/macrophages and/or exosomes. In addition, the TREM2 (R47H) mutation, 
which has been strongly linked with an increased risk of AD, was found in two DS 
participants, and in both, we observed gross morphological changes in megakaryocytes 
and erythrocytes, further supporting an aetiological link with neurodegeneration. The 
gene product of RUNX1 and hepcidin plays a vital role in haematopoiesis in DS. We 
propose that soluble TREM2, S100β and hepcidin, migrating from the periphery via the 
CP, modulate the blood–brain immune axis in DS and could form an important and 
hitherto neglected avenue for therapeutic intervention. 
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